Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BGI Genomics Raises $300 Million in Private Placement

publication date: Feb 22, 2021

BGI Genomics of Shenzhen raised almost $300 million for its next-gen sequencing services and genetic tests for medical institutions in a private placement. The company, which has been a major supplier of COVID-19 tests to global markets, raised capital to expand capacity and develop new products. Traditionally, it has focused on prenatal screening, hereditary cancer screening, testing for rare disease and precision medicine research. BGI Genomics is a part of BGI Group, one of the world’s largest genomics organizations. More details....

Stock Symbols: (SHZ: 300676)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021